News

The 15-week double-blind, randomized, placebo-controlled Phase IV trial enrolled a total of 107 adolescent patients from multiple centers across the US, Europe and Asia. This is the first

The company said that the original NDA has been amended to include data from the Phase III ALLY-3 trial, which tested a 12-week, ribavirin-free regimen and resulted in

The drug has been approved for use in combination with chlorambucil chemotherapy to treat adults with chronic lymphotic leukaemia (CLL). Gazyvaro is indicated to treat adults who are

LNA oligos offer dramatically improved sensitivity and specificity compared to traditional DNA chemistries. The amended agreement provides the company with access to LNA oligos for use with all

Pembrolizumab is marketed in the US under the name Keytruda. EAMS was introduced by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 2014 to help patients

In October 2010, the Japanese firm entered into an agreement with the Japan Health HS Foundation for the development of the HPV vaccine to prevent cervical cancer. Subsequently,

Lpathomab is a new antibody targeting Lysophosphatidic Acid (LPA), a bioactive lipid that has been characterized in the scientific literature as playing a major role in nerve injury

Endo said it would pay $175 per Salix share, which will include 1.4607 of its shares plus $45 in cash. Earlier in February, Canada-based Valeant Pharmaceuticals signed an

The MAA is based on positive data from the Phase III MYRROR trial, which randomized 122 patients to receive either aflibercept solution 2mg or sham. The multi-center, double-masked,